TY - JOUR
T1 - The associations between metabolic variables and NT-proBNP are blunted at pathological ranges
T2 - The Multi-Ethnic Study of Atherosclerosis
AU - Sanchez, Otto A.
AU - Duprez, Daniel A.
AU - Bahrami, Hossein
AU - Daniels, Lori B.
AU - Folsom, Aaron R.
AU - Lima, Joao A.
AU - Maisel, Alan
AU - Peralta, Carmen A.
AU - Jacobs, David R.
PY - 2014/4
Y1 - 2014/4
N2 - Objective Under physiological conditions brain natriuretic peptide (BNP) is inversely associated with metabolic risk factors, but under pathological conditions these associations may tend to plateau. Material and methods 5597 individuals in the Multi-Ethnic Study of Atherosclerosis (MESA), 45-84 years of age, free of overt cardiovascular disease in 2000-02 and then again in 2003-05 participated in this study. Associations between NT-proBNP and BMI, blood lipids, homeostasis model of insulin resistance (HOMA-IR) using linear regression models were adjusted for age, race, sex, BMI, % of energy from saturated fats, intentional exercise, statin use, antihypertensive medication use, diabetes and glomerular filtration rate. The inflection points (IP) at which these associations became nonlinear were determined using linear splines with knots at different levels of NT-proBNP. Results Participants with NT-proBNP ≥ 100 pg/mL (29%) tended to be older, on statins and anti-hypertensive medications vs. those with NT-proBNP < 100 pg/mL. The IP point varies among variables and ranged from 50-120 pg/mL. NT-proBNP < IP, associated inversely with BMI, total cholesterol (TC), LDL-C, triglycerides (TG) and HOMA-IR, but positively with HDL-C. A higher proportion of participants with NT-proBNP ≥ 100 pg/mL had subclinical CVD. All associations with NT-proBNP plateaued when NT-proBNP ≥ IP. Baseline level in NT-proBNP was not associated with 3-year change in BMI, TG, HDL-C or fasting glucose. Conclusions In a large cardiovascular disease-free cohort, NT-proBNP within the lower (physiological) range was inversely associated with TC, LDL-C, TG and insulin resistance with different inflection points, but at higher (pathological) levels these associations were blunted.
AB - Objective Under physiological conditions brain natriuretic peptide (BNP) is inversely associated with metabolic risk factors, but under pathological conditions these associations may tend to plateau. Material and methods 5597 individuals in the Multi-Ethnic Study of Atherosclerosis (MESA), 45-84 years of age, free of overt cardiovascular disease in 2000-02 and then again in 2003-05 participated in this study. Associations between NT-proBNP and BMI, blood lipids, homeostasis model of insulin resistance (HOMA-IR) using linear regression models were adjusted for age, race, sex, BMI, % of energy from saturated fats, intentional exercise, statin use, antihypertensive medication use, diabetes and glomerular filtration rate. The inflection points (IP) at which these associations became nonlinear were determined using linear splines with knots at different levels of NT-proBNP. Results Participants with NT-proBNP ≥ 100 pg/mL (29%) tended to be older, on statins and anti-hypertensive medications vs. those with NT-proBNP < 100 pg/mL. The IP point varies among variables and ranged from 50-120 pg/mL. NT-proBNP < IP, associated inversely with BMI, total cholesterol (TC), LDL-C, triglycerides (TG) and HOMA-IR, but positively with HDL-C. A higher proportion of participants with NT-proBNP ≥ 100 pg/mL had subclinical CVD. All associations with NT-proBNP plateaued when NT-proBNP ≥ IP. Baseline level in NT-proBNP was not associated with 3-year change in BMI, TG, HDL-C or fasting glucose. Conclusions In a large cardiovascular disease-free cohort, NT-proBNP within the lower (physiological) range was inversely associated with TC, LDL-C, TG and insulin resistance with different inflection points, but at higher (pathological) levels these associations were blunted.
KW - BMI
KW - HOMA
KW - Inflammatory markers
KW - Lipids
KW - NT-proBNP
UR - http://www.scopus.com/inward/record.url?scp=84896495215&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84896495215&partnerID=8YFLogxK
U2 - 10.1016/j.metabol.2013.11.017
DO - 10.1016/j.metabol.2013.11.017
M3 - Article
C2 - 24388001
AN - SCOPUS:84896495215
VL - 63
SP - 475
EP - 483
JO - Metabolism: Clinical and Experimental
JF - Metabolism: Clinical and Experimental
SN - 0026-0495
IS - 4
ER -